Literature DB >> 11816263

Inhibition of warfarin activity by ribavirin.

Sam Schulman1.   

Abstract

OBJECTIVE: To report a case of inhibition of the effect of warfarin during treatment with ribavirin. CASE
SUMMARY: A 61-year-old white man received combination treatment with interferon and ribavirin during 1 year for chronic hepatitis C. He was on permanent anticoagulant therapy with warfarin after a previous heart valve replacement. The dose of warfarin had to be increased by approximately 40% to maintain the desired level of anticoagulation. DISCUSSION: Interferon has previously been reported to potentiate the effect of warfarin. This is the first case published in the English-language literature describing an inhibition of the effect of warfarin by the combination of interferon and ribavirin. A rechallenge with ribavirin demonstrated that the inhibition of warfarin could be reproduced. The mechanism for this interaction is unclear. The pharmacokinetics of ribavirin and the potential pathways for interaction are discussed.
CONCLUSIONS: During 4 weeks after starting or discontinuing treatment with ribavirin, prothrombin time may be affected in patients receiving warfarin for anticoagulation. It seems prudent to monitor warfarin therapy more frequently during those periods.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11816263     DOI: 10.1345/aph.1A181

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  10 in total

1.  Ribavirin in the treatment of SARS: A new trick for an old drug?

Authors:  Gideon Koren; Susan King; Sandra Knowles; Elizabeth Phillips
Journal:  CMAJ       Date:  2003-05-13       Impact factor: 8.262

Review 2.  The oncologic burden of hepatitis C virus infection: A clinical perspective.

Authors:  Harrys A Torres; Terri Lynn Shigle; Nassim Hammoudi; James T Link; Felipe Samaniego; Ahmed Kaseb; Vincent Mallet
Journal:  CA Cancer J Clin       Date:  2017-07-06       Impact factor: 508.702

Review 3.  The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review.

Authors:  Mohammed Ahmed Akkaif; Abubakar Sha'aban; Arturo Cesaro; Ammar Ali Saleh Jaber; Andrea Vergara; Ismaeel Yunusa; Abubakar Ibrahim Jatau; Mustapha Mohammed; G Saravana Govindasamy; Majed Ahmed Al-Mansoub; Muhamad Ali Sheikh Abdul Kader; Baharudin Ibrahim
Journal:  Inflammopharmacology       Date:  2022-06-14       Impact factor: 5.093

4.  Warfarin and boceprevir interaction causing subtherapeutic international normalized ratio: a case report.

Authors:  Andrew S Tsiattalos; Anita Patel
Journal:  J Med Case Rep       Date:  2014-12-17

Review 5.  A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs.

Authors:  Wen-Liang Yu; Han Siong Toh; Chia-Te Liao; Wei-Ting Chang
Journal:  Cardiovasc Drugs Ther       Date:  2020-06-17       Impact factor: 3.727

Review 6.  Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement.

Authors:  Hamideh Amirfakhryan; Fatemeh Safari
Journal:  Hellenic J Cardiol       Date:  2020-06-06

Review 7.  COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review.

Authors:  Behnood Bikdeli; Mahesh V Madhavan; David Jimenez; Taylor Chuich; Isaac Dreyfus; Elissa Driggin; Caroline Der Nigoghossian; Walter Ageno; Mohammad Madjid; Yutao Guo; Liang V Tang; Yu Hu; Jay Giri; Mary Cushman; Isabelle Quéré; Evangelos P Dimakakos; C Michael Gibson; Giuseppe Lippi; Emmanuel J Favaloro; Jawed Fareed; Joseph A Caprini; Alfonso J Tafur; John R Burton; Dominic P Francese; Elizabeth Y Wang; Anna Falanga; Claire McLintock; Beverley J Hunt; Alex C Spyropoulos; Geoffrey D Barnes; John W Eikelboom; Ido Weinberg; Sam Schulman; Marc Carrier; Gregory Piazza; Joshua A Beckman; P Gabriel Steg; Gregg W Stone; Stephan Rosenkranz; Samuel Z Goldhaber; Sahil A Parikh; Manuel Monreal; Harlan M Krumholz; Stavros V Konstantinides; Jeffrey I Weitz; Gregory Y H Lip
Journal:  J Am Coll Cardiol       Date:  2020-04-17       Impact factor: 24.094

Review 8.  Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.

Authors:  Haleh Rezaee; Fariba Pourkarim; Samira Pourtaghi-Anvarian; Taher Entezari-Maleki; Touraj Asvadi-Kermani; Masoud Nouri-Vaskeh
Journal:  Pharmacol Res Perspect       Date:  2021-02

Review 9.  Guidance on Short-Term Management of Atrial Fibrillation in Coronavirus Disease 2019.

Authors:  Pattara Rattanawong; Win Shen; Hicham El Masry; Dan Sorajja; Komandoor Srivathsan; Arturo Valverde; Luis R Scott
Journal:  J Am Heart Assoc       Date:  2020-06-09       Impact factor: 5.501

Review 10.  Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.

Authors:  Catherine Hodge; Fiona Marra; Catia Marzolini; Alison Boyle; Sara Gibbons; Marco Siccardi; David Burger; David Back; Saye Khoo
Journal:  J Antimicrob Chemother       Date:  2020-12-01       Impact factor: 5.790

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.